U.S. patent application number 15/709516 was filed with the patent office on 2019-03-21 for method for treating male sexual dysfunction by using underpants comprising far-infrared fibers.
The applicant listed for this patent is GREEN ENERGY NANO TECHNOLOGY CO., LTD.. Invention is credited to Tien-Show Liang.
Application Number | 20190083807 15/709516 |
Document ID | / |
Family ID | 65719724 |
Filed Date | 2019-03-21 |
![](/patent/app/20190083807/US20190083807A1-20190321-C00001.png)
![](/patent/app/20190083807/US20190083807A1-20190321-C00002.png)
![](/patent/app/20190083807/US20190083807A1-20190321-C00003.png)
![](/patent/app/20190083807/US20190083807A1-20190321-D00000.png)
![](/patent/app/20190083807/US20190083807A1-20190321-D00001.png)
![](/patent/app/20190083807/US20190083807A1-20190321-D00002.png)
![](/patent/app/20190083807/US20190083807A1-20190321-D00003.png)
![](/patent/app/20190083807/US20190083807A1-20190321-D00004.png)
![](/patent/app/20190083807/US20190083807A1-20190321-D00005.png)
![](/patent/app/20190083807/US20190083807A1-20190321-D00006.png)
![](/patent/app/20190083807/US20190083807A1-20190321-D00007.png)
View All Diagrams
United States Patent
Application |
20190083807 |
Kind Code |
A1 |
Liang; Tien-Show |
March 21, 2019 |
METHOD FOR TREATING MALE SEXUAL DYSFUNCTION BY USING UNDERPANTS
COMPRISING FAR-INFRARED FIBERS
Abstract
Differing from conventional approaches for improving sexual
dysfunction of an adult man being commonly carried out by letting
the adult man administer a dosage of synthetic drug or a
composition of Chinese herbal medicines, the present invention
particularly discloses a method for treating male sexual
dysfunction by using underpants comprising far-infrared fibers. A
variety of clinical data have proved that, after wearing this
underpants for 3 months, both the men diagnosed with sexual
dysfunction and the men not sure to suffer from sexual dysfunction
have an apparent progress on improvements of their erectile
ability, erectile quality, ejaculation control ability, and lower
urinary tract symptoms (LUTS). Moreover, clinical data have also
proved that, despite the fact that a male person wears the
underpants provided by the present invention for three months,
there is no adverse effect induced by the underpants for causing
the physiological condition of the men be abnormal.
Inventors: |
Liang; Tien-Show; (Taipei
City, TW) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
GREEN ENERGY NANO TECHNOLOGY CO., LTD. |
Taipei City |
|
TW |
|
|
Family ID: |
65719724 |
Appl. No.: |
15/709516 |
Filed: |
September 20, 2017 |
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
G09B 3/10 20130101; A61N
2005/066 20130101; A41B 9/02 20130101; A41B 2400/32 20130101; A61N
2005/0645 20130101; G09B 3/06 20130101; A61N 5/0613 20130101; A61N
2005/063 20130101; A41B 17/00 20130101; A41B 2500/20 20130101 |
International
Class: |
A61N 5/06 20060101
A61N005/06; A41B 9/02 20060101 A41B009/02; A41B 17/00 20060101
A41B017/00; G09B 3/10 20060101 G09B003/10; G09B 3/06 20060101
G09B003/06 |
Claims
1. A method for treating male sexual dysfunction by using
underpants comprising far-infrared fibers, comprising following
steps: (1) providing an underpants weaved from a plurality of
far-infrared fibers and a plurality of fibers, wherein each of the
far-infrared fibers comprises a polymer sheath and far-infrared
powders doped in or enclosed by the polymer sheath; moreover, the
far-infrared fibers having a fiber amount occupying 20-50 percent
of a total fiber amount of the underpants; and (2) letting adult
men diagnosed with sexual dysfunction or not sure to suffer from
sexual dysfunction wear the underpants for at least one month.
2. The method of claim 1, wherein the type of the underpants is
selected from the group consisting of briefs, boxer briefs and
boxer shorts.
3. The method of claim 1, wherein the manufacturing material of the
polymer sheath is selected from the group consisting of polyester
(PET), polyurethane (PU), Poly(vinyl chloride) (PVC), poly
propylene (PP), and polyamide (PA).
4. The method of claim 1, wherein the polymer sheath is made of a
polymer compound comprising silica of at least 50 wt %, and the
chemical structure of the polymer compound is presented by
following chemical formula 1: ##STR00002## wherein n in the
chemical formula 1 is in a range from 50 to 100.
5. The method of claim 1, wherein the far-infrared powders
comprises powdered titanium (Ti) with a first metal weight percent
of 11-18 wt %, powdered germanium (Ge) with a second metal weight
percent of 0.1-0.2 wt % and powdered zinc (Zn) with a third metal
weight percent of 0.05-0.15 wt %.
6. The method of claim 5, wherein the far-infrared fibers are able
to emit a far-infrared ray with a wavelength in a range from 2
.mu.m to 22 .mu.m, and the emissivity of the far-infrared ray is
above 90%.
7. The method of claim 1, wherein the far-infrared powders further
comprises powdered oxide and powdered carbide for increasing the
emissivity of the far-infrared ray.
8. The method of claim 7, wherein the powdered oxide is selected
from the group consisting of: Al.sub.2O.sub.3, MgO, NiO.sub.2,
SiO.sub.2, ZrO.sub.2, and a mixture made by any two or more
aforesaid materials.
9. The method of claim 7, wherein the powdered carbide is selected
from the group consisting of: TaC, ZrC, SiC, and a mixture made by
any two or more aforesaid materials.
10. A method for treating male sexual dysfunction by using
underpants comprising far-infrared fibers, comprising following
steps: (1) providing an underpants weaved from a plurality of
far-infrared fibers, wherein each of the far-infrared fibers
comprises a polymer sheath and far-infrared powders doped in or
enclosed by the polymer sheath; and (2) letting adult men diagnosed
with sexual dysfunction or not sure to suffer from sexual
dysfunction wear the underpants for at least one month.
11. The method of claim 10, wherein the type of the underpants is
selected from the group consisting of briefs, boxer briefs and
boxer shorts.
12. The method of claim 10, wherein the manufacturing material of
the polymer sheath is selected from the group consisting of
polyester (PET), polyurethane (PU), Poly(vinyl chloride) (PVC),
poly propylene (PP), and polyamide (PA).
13. The method of claim 10, wherein the polymer sheath is made of a
polymer compound comprising silica of at least 50 wt %, and the
chemical structure of the polymer compound is presented by
following chemical formula 1: ##STR00003## wherein n in the
chemical formula 1 is in a range from 50 to 100.
14. The method of claim 10, wherein the far-infrared powders
comprises powdered titanium (Ti) with a first metal weight percent
of 11-18 wt %, powdered germanium (Ge) with a second metal weight
percent of 0.1-0.2 wt % and powdered zinc (Zn) with a third metal
weight percent of 0.05-0.15 wt %.
15. The method of claim 14, wherein the far-infrared fibers are
able to emit a far-infrared ray with a wavelength in a range from 2
.mu.m to 22 .mu.m, and the emissivity of the far-infrared ray is
above 90%.
16. The method of claim 14, wherein the far-infrared powders
further comprises powdered oxide and powdered carbide for
increasing the emissivity of the far-infrared ray.
17. The method of claim 16, wherein the powdered oxide is selected
from the group consisting of: Al.sub.2O.sub.3, MgO, NiO.sub.2,
SiO.sub.2, ZrO.sub.2, and a mixture made by any two or more
aforesaid materials.
18. The method of claim 16, wherein the powdered carbide is
selected from the group consisting of: TaC, ZrC, SiC, and a mixture
made by any two or more aforesaid materials.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention
[0001] The present invention relates to the technology field of
far-infrared fibers, and more particularly to a method for treating
male sexual dysfunction by using underpants comprising far-infrared
fibers.
2. Description of the Prior Art
[0002] Male sexual dysfunction includes erectile dysfunction (ED),
premature ejaculation (PE), delayed ejaculation, and low libido,
wherein mental factors, physiological factors and drug factors are
known able to cause the male sexual dysfunction. Moreover, clinical
research reports that mental factor may formed by melancholia, low
self-confidence, and anxiety of sexual performance, and the
physiological factor is commonly resulted from cardiovascular
diseases, endocrine system diseases and disorders, or injury or
fracture of penile corpus cavernosum.
[0003] Statistical data indicate that, about half of all men
between the ages of 40 and 70 suffer from erectile dysfunction (ED)
to some degree. ED is one of the most common chronic diseases
affecting men and its prevalence increases with aging.
[0004] Phosphodiesterase-5 inhibitors (PDE5-I) are commonly used
for on-demand or chronic treatment of ED. Viagra (sildenafil),
Levitra (vardenafil) and Cialis (tadalafil) are currently known
prescription ED drugs comprising PDE5-I. By dilating blood vessels
and relaxing smooth muscle tissues in penis, these drugs
successfully improve or treat erectile dysfunction. However, this
is the result of a series of conditions occurring simultaneously.
When ED drug is taken correctly, it is no longer a concern.
Nevertheless, in the mind of the public, use of the ED drug is at
this time invariably considered dangerous for patients with heart
disease. Moreover, it is well known that these ED drugs may cause
unwanted side effects that require medical attention.
[0005] In view of the fact that most of ED drugs induce unwanted
side effects, U.S. Pat. No. 7,147,874 discloses a pharmaceutical
composition for prevention and treatment of premature ejaculation.
The pharmaceutical composition comprises an extract of Bufonis
Venenum and an extract of Ginseng. To carry out treatment of
premature ejaculation, 0.2 g of gel pharmaceutical composition is
applied to an adult man's penis glans, such that the contraction of
penile smooth muscle is reduced so as to extend erection time of
the adult man. However, the pharmaceutical composition is just used
to prevent men from premature ejaculation during his sexual
intercourse, but fail to provide a real improvement on solving
sexual dysfunction to the men.
[0006] Accordingly, U.S. Pat. No. 8,211,006 discloses a penis
erection stabilizer. FIG. 1 shows a stereo diagram of the penis
erection stabilizer. From FIG. 1, it is understood that the penis
erection stabilizer 1' comprises a stabilizer body 11' and a
through-hole 12' defined through a center portion of the stabilizer
body 11'. It is well know that, the blood supplied to the spongy
tissue of an adult man's penis would flow back via vein when the
adult man ejaculates or loses tension due to fatigue under sexual
intercourse. In the meantime, because the adult man's penis is
sleeved with the penis erection stabilizer 1', the blood in the
expanded penis should first pass through a small diameter portion
of the through-hole 12', such that the small diameter portion keeps
the blood so as to retard the discharge of the blood. Eventually,
the erected state of the penis can be maintained for a time
sufficient for the completion of the sexual intercourse. It is
worth noting that, owing to the fact that the use way of the penis
erection stabilizer 1' is to sleeve on user's penis, it is
presumably that frequently-repeating use of the penis erection
stabilizer 1' would cause the injury of the penis.
[0007] From above descriptions, it is clear that both the
pharmaceutical composition for prevention of premature ejaculation
and the penis erection stabilizer 1' show practical-application
drawbacks. In view of that, inventors of the present application
have made great efforts to make inventive research thereon and
eventually provided a method for treating male sexual dysfunction
by using underpants comprising far-infrared fibers.
SUMMARY OF THE INVENTION
[0008] Differing from the fact that conventional approaches for
improving sexual dysfunction of an adult man are commonly carried
out by letting the adult man administer a dosage of synthetic drug
or a composition of Chinese herbal medicines, the present invention
particularly discloses a method for treating male sexual
dysfunction by using underpants comprising far-infrared fibers. A
variety of clinical data have proved that, after wearing this
underpants for 3 months, both the men diagnosed with sexual
dysfunction and the men not sure to suffer from sexual dysfunction
have an apparent progress on improvements of their erectile
ability, erectile quality, ejaculation control ability, and lower
urinary tract symptoms (LUTS). Moreover, clinical data have also
proved that, despite the fact that a male person wears the
underpants provided by the present invention for three months,
there is no any adverse effect induced by the underpants so as to
cause the physiological condition of the men be abnormal.
[0009] In order to achieve the primary objective of the present
invention, the inventor of the present invention provides an
embodiment of the method for treating male sexual dysfunction by
using underpants, comprising following steps: [0010] (1) providing
an underpants weaved from a plurality of far-infrared fibers and a
plurality of fibers, wherein each of the far-infrared fibers
comprises a polymer sheath and far-infrared metal powders doped in
or enclosed by the polymer sheath; moreover, the far-infrared
fibers having a fiber amount occupying 40-60 percent of a total
fiber amount of the underpants; and [0011] (2) letting adult men
diagnosed with sexual dysfunction or not sure to suffer from sexual
dysfunction wear the underpants for at least one month.
[0012] Moreover, for achieving the primary objective of the present
invention, the inventor of the present invention further provides
another one embodiment of the method for treating male sexual
dysfunction by using underpants, comprising following steps: [0013]
(1) providing an underpants weaved from a plurality of far-infrared
fibers, wherein each of the far-infrared fibers comprises a polymer
sheath and far-infrared powders doped in or enclosed by the polymer
sheath; and [0014] (2) letting adult men diagnosed with sexual
dysfunction or not sure to suffer from sexual dysfunction wear the
underpants for at least one month.
[0015] In the two embodiments of the method, wherein the type of
the underpants is selected from the group consisting of briefs,
boxer briefs and boxer shorts.
[0016] In the two embodiments of the method, wherein the
far-infrared powders comprises powdered titanium (Ti) with a first
metal weight percent of 11-18 wt %, powdered germanium (Ge) with a
second metal weight percent of 0.1-0.2 wt % and powdered zinc (Zn)
with a third metal weight percent of 0.05-0.15 wt %.
[0017] In the two embodiments of the method, wherein the
far-infrared fibers are able to emit a far-infrared ray with a
wavelength in a range from 2 .mu.m to 22 .mu.m, and the emissivity
of the far-infrared ray is above 90%.
[0018] In the two embodiments of the method, wherein the
far-infrared powders further comprises powdered oxide and powdered
carbide for increasing the emissivity of the far-infrared ray.
[0019] In the two embodiments of the method, wherein the
far-infrared powders further comprises other powdered metal
selected from the group consisting of powdered copper (Cu),
powdered silver (Ag), powdered aluminum (Al), powdered magnesium
(Mg), a mixture made by any two or more aforesaid materials.
BRIEF DESCRIPTION OF THE DRAWINGS
[0020] The invention as well as a preferred mode of use and
advantages thereof will be best understood by referring to the
following detailed description of an illustrative embodiment in
conjunction with the accompanying drawings, wherein:
[0021] FIG. 1 shows a stereo diagram of a penis erection
stabilizer;
[0022] FIG. 2A and FIG. 2B show stereo diagrams of a first
embodiment of an underpants capable of improving male sexual
dysfunction;
[0023] FIG. 3 shows a cross-sectional view of one far-infrared
fiber;
[0024] FIG. 4A, FIG. 4B and FIG. 4C show a schematic production
processing flow of the underpants capable of improving male sexual
dysfunction;
[0025] FIG. 5 shows a stereo diagram of a second embodiment of the
underpants capable of improving male sexual dysfunction;
[0026] FIG. 6 shows a stereo diagram of a third embodiment of the
underpants capable of improving male sexual dysfunction;
[0027] FIG. 7 shows a diagram for introducing an IIEF-5
questionnaire;
[0028] FIG. 8 shows a diagram for introducing a QEQ
questionnaire;
[0029] FIG. 9 shows a diagram for introducing a PEDT
questionnaire;
[0030] FIG. 10 shows a diagram for introducing an IPSS
questionnaire;
[0031] FIG. 11 shows a data graph of time of clinical experiment
versus average score of questionnaire;
[0032] FIG. 12 shows a data graph of time of clinical experiment
versus average score of questionnaire;
[0033] FIG. 13 shows a data graph for describing questionnaire
score variation between adjacent two months;
[0034] FIG. 14 shows a data graph for describing questionnaire
score variation between adjacent two months;
[0035] FIG. 15 shows a data graph of time of clinical experiment
versus average score of questionnaire;
[0036] FIG. 16 shows a data graph of time of clinical experiment
versus average score of questionnaire;
[0037] FIG. 17 shows a data graph for describing questionnaire
score variation between adjacent two months;
[0038] FIG. 18 shows a data graph for describing questionnaire
score variation between adjacent two months;
[0039] FIG. 19 shows a data graph of time of clinical experiment
versus average score of questionnaire;
[0040] FIG. 20 shows a data graph of time of clinical experiment
versus average score of questionnaire;
[0041] FIG. 21 shows a data graph for describing questionnaire
score variation between adjacent two months;
[0042] FIG. 22 shows a data graph for describing questionnaire
score variation between adjacent two months;
[0043] FIG. 23 shows a data graph of time of clinical experiment
versus average score of questionnaire;
[0044] FIG. 24 shows a data graph of time of clinical experiment
versus average score of questionnaire;
[0045] FIG. 25 shows a data graph for describing questionnaire
score variation between adjacent two months; and
[0046] FIG. 26 shows a data graph for describing questionnaire
score variation between adjacent two months.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0047] To more clearly describe a method for treating male sexual
dysfunction by using underpants comprising far-infrared fibers
according to the present invention, embodiments of the present
invention will be described in detail with reference to the
attached drawings hereinafter.
First Embodiment
[0048] The inventors of the present invention find that the
underpants comprising far-infrared fibers has a particular function
to improve male sexual dysfunction. Please refer to FIG. 2A and
FIG. 2B, where stereo diagrams of a first embodiment of an
underpants capable of improving male sexual dysfunction are
provided. According to FIG. 2A and FIG. 2B, it is understood that
the underpants 1 capable of improving male sexual dysfunction is
weaved from a plurality of far-infrared fibers 11 and a plurality
of fibers 12, wherein the far-infrared fibers 11 has a fiber amount
occupying 20-50 percent of a total fiber amount of the underpants
1. For instance, FIG. 2A and FIG. 2B indicate that the front rise
portion 13 and the crotch portion 14 of the underpants 1 is
constituted by the far-infrared fibers 11, and other portions of
the underpants 1 is weaved from the fibers 12.
[0049] FIG. 3 shows a cross-sectional view of one far-infrared
fiber. In the present invention, the far-infrared fiber 11
comprises a polymer sheath 111 and far-infrared powders 112 doped
in or enclosed by the polymer sheath 111. Moreover, the
manufacturing material of the polymer sheath 111 is selected from
the group consisting of polyester (PET), polyurethane (PU),
Poly(vinyl chloride) (PVC), poly propylene (PP), and polyamide
(PA). It is worth explaining that, vinyl contains phthalate
chemicals or similar plasticizers that are used to turn hard
polyvinyl chloride (PVC) into soft and pliable vinyl. Related
research reports that phthalates are animal carcinogens and can
cause fetal death, malformations, and reproductive toxicity in
laboratory animals. Based on the reasons, the polymer sheath 11 can
also be made of a polymer compound comprising silica of at least 50
wt %, wherein the chemical structure of the polymer compound is
presented by following chemical formula 1.
##STR00001##
[0050] In chemical formula 1, n is an integer in a range from 50 to
100. On the other hand, the far-infrared powders comprises powdered
titanium (Ti) with a first metal weight percent of 11-18 wt %,
powdered germanium (Ge) with a second metal weight percent of
0.1-0.2 wt % and powdered zinc (Zn) with a third metal weight
percent of 0.05-0.15 wt %. By such arrangement, when an adult man
wear this underpants 1, the far-infrared ray emitted from the front
rise portion 13 and the crotch portion 14 of the underpants 1 would
make the dilation of penile arteries of the adult man, and
simultaneously urge blood to flow into the penile arteries so as to
make the erection of the adult man's penis.
[0051] It needs further explain that, the far-infrared powders 112
further comprises powdered oxide and powdered carbide for
increasing the emissivity of the far-infrared ray of the
far-infrared fibers 11, wherein the powdered oxide is selected from
the group consisting of: Al.sub.2O.sub.3, MgO, NiO.sub.2,
SiO.sub.2, ZrO.sub.2, and a mixture made by any two or more
aforesaid materials. Moreover, the powdered carbide is selected
from the group consisting of: TaC, ZrC, SiC, and a mixture made by
any two or more aforesaid materials. By such arrangement, the front
rise portion 13 and the crotch portion 14 of the underpants 1 are
able to emit the far-infrared ray having an emissivity greater than
90% and a wavelength of 2-22 .mu.m. In addition, other powdered
metal such as powdered copper (Cu), powdered silver (Ag), powdered
aluminum (Al), or powdered magnesium (Mg) can also be mixed into
the far-infrared powders 112.
[0052] FIG. 4A, FIG. 4B and FIG. 4C show a schematic production
processing flow of the underpants capable of improving male sexual
dysfunction. The underpants 1 capable of improving male sexual
dysfunction is manufactured through following process flow: [0053]
step (1): as FIG. 4A shows, to add far-infrared powders 112 into a
polymer solution 111a, and then convert the polymer solution 111a
to a plurality of masterbatches 2 through polymerization and
granulation process; [0054] step (2): as FIG. 4B shows, executing a
spinning process for drawing the masterbatches 2 to a plurality of
far-infrared fibers 11; and [0055] step (3): as FIG. 4C shows, the
underpants 1 capable of improving male sexual dysfunction is weaved
from the far-infrared fibers 11 and a plurality of fibers 12.
Second Embodiment
[0056] It needs to emphasize that, in spite of the fact that the
fiber content of the far-infrared fibers 11 of the underpants 1 is
in a range from 20% to 50%, that does not used for limiting the
constitution of the underpants 1. In the first embodiment, what is
weaved from the far-infrared fibers 11 are only the front rise
portion 13 and the crotch portion 14 of the underpants 1, with the
purpose of cost saving. Please refer to FIG. 5, which illustrates a
stereo diagram of a second embodiment of the underpants capable of
improving male sexual dysfunction. After comparing FIG. 2B with
FIG. 5, it is found that the underpants 1 shown in FIG. 5 is a
blend fabric of the far-infrared fibers 11 and the fibers 12,
wherein the far-infrared fibers 11 has a maximum fiber amount
occupying 50 percent of a total fiber amount of the underpants 1.
However, for business benefit consideration, the far-infrared
fibers 11 content of the underpants 1 must be limited to lower than
50% because the cost of the far-infrared fibers 11 is higher than
the general fibers' 12.
Third Embodiment
[0057] Of course, the far-infrared fibers 11 content of the
underpants 1 may be greater than 50% without the consideration of
business benefit. FIG. 6 shows a stereo diagram of a third
embodiment of the underpants capable of improving male sexual
dysfunction. Compared FIG. 5 with FIG. 6, it is understood that the
underpants 1 shown in FIG. 6 is weaved merely from the far-infrared
fibers 11, such that the far-infrared fibers 11 content of the
underpants 1 is 100%.
[0058] First Clinical Trials
[0059] A clinical trial is, essentially, any form of planned
experiment that involves patients and is designed to elucidate the
most effective treatment for patients with the underpants 1 weaved
from the far-infrared fibers 11 and the fibers 12. More
particularly, first clinical trials are typically utilized to
evaluate the effectiveness of the underpants 1 on improving sexual
dysfunction of adult men. According to following Table (1), adult
men diagnosed with sexual dysfunction are chosen as test subjects,
and further divided into control group (abbreviated to group C) and
experimental group (abbreviated to group E) for completing 3-month
clinical trials. It needs to further explain that, both the adult
men of the group C and the group E wear the underpants 1 provided
by the present invention. Moreover, the primary difference between
the group C and the group E is that the adult men of the group C
has been informed that the underpants they wore is a commercial
underpants. On the other hand, in Table (1), physiology examination
reports to be "abnormal" means the adult men suffer from
hypertension.
TABLE-US-00001 TABLE (1) Physiology Age BMI examination Standard
Over Normal Abnormal Average .+-. deviation Normal weight Obese
Group C 3 1 49 .+-. 8.18 2 2 0 (n = 4) Group E 4 1 47 .+-. 6.45 2 3
0 (n = 5)
[0060] What is needed to emphasize is that the adult men are chosen
as the test subjects after passing the following exclusion
criteria: [0061] (1) ever using sex hormone agents or PDE-5
inhibitors like Sildenafil, Vardenafil, or Tadalafil administered
in the 7 days previously for the treatment of male sexual
dysfunction; [0062] (2) a long user of antihypertensive drugs,
antidepressants, sedatives, anti-androgens, or medicines for
treating peptic ulcer; [0063] (3) ever being subject to serious
injuries of central system, for example, stroke or spinal cord
injury; [0064] (4) ever suffering from erectile disorder caused by
non-vascular diseases factors, such as nervous factors or hormone
factors; [0065] (5) being an HIV patient or the patient with liver
disease; [0066] (6) diagnosis of urethral stricture, urinary tract
infection, prostatitis, prostate cancer, or bladder cancer; [0067]
(7) sexual partner is pregnant or in a breast-feeding period;
[0068] (8) being a patient with Peyronie's disease; [0069] (9)
suffering from alcoholism or tobacco addiction; [0070] (10)
suffering from cancer of prostate gland or other malignant
neoplasms; [0071] (11) will have an operation (surgical treatment)
during clinical trials period; [0072] (12) having an unhealthy
mental status which will affect evaluations of clinical trials;
[0073] (13) ever completing at least one sexual performance test
which will affect evaluations of clinical trials; and [0074] (14)
being ineligibility for the current study judged by
investigators.
[0075] During 3-month clinical trials, the test subjects are
requested to come back for follow up at the hospital every 1 month
for completing the filling of four questionnaires of IIEF-5, QEQ,
PEDT, and IPSS. Moreover, physiological data of the test subjects
are also measured and recorded by nursing personnel. Diagrams of
IIEF-5 questionnaire, QEQ questionnaire, PEDT questionnaire, and
IPSS questionnaire are displayed in FIG. 7, FIG. 8, FIG. 9, and
FIG. 10, respectively.
[0076] Moreover, FIG. 11 shows a data graph of time of clinical
experiment versus average score of questionnaire, and FIG. 12 shows
a data graph of time of clinical experiment versus average score of
questionnaire. From the data of clinical trials provided in FIG. 11
and FIG. 12, it is found that, compared to the adult men wearing
the underpants provided by the present invention for one month, the
adult men wearing the underpants provided by the present invention
for three months have an apparent progress on improvements of their
erectile ability and erectile quality. On the other hand, FIG. 13
shows a data graph for describing questionnaire score variation
between adjacent two months and FIG. 14 shows a data graph for
describing questionnaire score variation between adjacent two
months. From the data of clinical trials provided in FIG. 13 and
FIG. 14, it is further understood that, the adult men wearing the
underpants provided by the present invention for three months have
an apparent progress on improvements of their erectile ability and
erectile quality, compared to the adult men wearing the underpants
provided by the present invention for one month.
[0077] In addition, FIG. 15 shows a data graph of time of clinical
experiment versus average score of questionnaire, and FIG. 16 shows
a data graph of time of clinical experiment versus average score of
questionnaire. From the data of clinical trials provided in FIG. 15
and FIG. 16, it is found that, compared to the adult men wearing
the underpants provided by the present invention for one month, the
adult men wearing the underpants provided by the present invention
for three months have an apparent progress on improvements of their
ejaculation control ability and lower urinary tract symptoms
(LUTS). On the other hand, FIG. 17 shows a data graph for
describing questionnaire score variation between adjacent two
months and FIG. 18 shows a data graph for describing questionnaire
score variation between adjacent two months. From the data of
clinical trials provided in FIG. 17 and FIG. 18, it is further
understood that, the adult men wearing the underpants provided by
the present invention for three months have an apparent progress on
improvements of their ejaculation control ability and lower urinary
tract symptoms (LUTS), compared to the adult men wearing the
underpants provided by the present invention for one month.
[0078] Second Clinical Trials
[0079] Second clinical trials are planned for verifying the
accuracy of the data corrected from the first clinical trials.
According to following Table (2), adult men not sure to suffer from
sexual dysfunction are chosen as test subjects, and further divided
into control group (abbreviated to group C) and experimental group
(abbreviated to group E) for completing 3-month clinical trials. It
needs to further explain that, both the adult men of the group C
and the group E wear the underpants 1 provided by the present
invention. Moreover, the primary difference between the group C and
the group E is that the adult men of the group C has been informed
that the underpants they wore is a commercial underpants. On the
other hand, in Table (2), physiology examination reports to be
"abnormal" means the adult men suffer from hypertension.
TABLE-US-00002 TABLE (2) Physiology Age BMI examination Standard
Over Normal Abnormal Avg. .+-. deviation Normal weight Obese Group
C 4 1 46.66 .+-. 5.36 2 3 0 (n = 5) Group E 13 1 48.93 .+-. 7.45 2
8 4 (n = 14)
[0080] During 3-month clinical trials, the test subjects are
requested to come back for follow up at the hospital every 1 month
for completing the filling of four questionnaires of IIEF-5, QEQ,
PEDT, and IPSS. Moreover, physiological data of the test subjects
are also measured and recorded by nursing personnel. Diagrams of
IIEF-5 questionnaire, QEQ questionnaire, PEDT questionnaire, and
IPSS questionnaire are displayed in FIG. 19, FIG. 20, FIG. 21, and
FIG. 22, respectively. FIG. 19 shows a data graph of time of
clinical experiment versus average score of questionnaire, and FIG.
20 shows a data graph of time of clinical experiment versus average
score of questionnaire. From the data of clinical trials provided
in FIG. 19 and FIG. 20, it is found that, compared to the adult men
wearing the underpants provided by the present invention for one
month, the adult men wearing the underpants provided by the present
invention for three months have an apparent progress on
improvements of their erectile ability and erectile quality. On the
other hand, FIG. 21 shows a data graph for describing questionnaire
score variation between adjacent two months and FIG. 22 shows a
data graph for describing questionnaire score variation between
adjacent two months. From the data of clinical trials provided in
FIG. 21 and FIG. 22, it is further understood that, the adult men
wearing the underpants provided by the present invention for three
months have an apparent progress on improvements of their erectile
ability and erectile quality, compared to the adult men wearing the
underpants provided by the present invention for one month.
[0081] In addition, FIG. 23 shows a data graph of time of clinical
experiment versus average score of questionnaire, and FIG. 24 shows
a data graph of time of clinical experiment versus average score of
questionnaire. From the data of clinical trials provided in FIG. 23
and FIG. 24, it is found that, compared to the adult men wearing
the underpants provided by the present invention for one month, the
adult men wearing the underpants provided by the present invention
for three months have an apparent progress on improvements of their
ejaculation control ability and lower urinary tract symptoms
(LUTS). On the other hand, FIG. 25 shows a data graph for
describing questionnaire score variation between adjacent two
months and FIG. 26 shows a data graph for describing questionnaire
score variation between adjacent two months. From the data of
clinical trials provided in FIG. 25 and FIG. 26, it is further
understood that, the adult men wearing the underpants provided by
the present invention for three months have an apparent progress on
improvements of their ejaculation control ability and lower urinary
tract symptoms (LUTS), compared to the adult men wearing the
underpants provided by the present invention for one month.
[0082] Furthermore, data of FIG. 11-FIG. 26 are integrated in
following Table (3) and Table (4).
TABLE-US-00003 TABLE (3) First month Third month Avg. Avg.
Improvement status Group C of Standard of Standard P Questionnaire
score .+-. deviation score .+-. deviation unimproved unimproved
value IIEF-5 17.7 .+-. 8.53 17.33 .+-. 8.51 0.92 QEQ 19.30 .+-.
8.46 18.11 .+-. 8.34 0.76 PEDT 6.3 .+-. 5.21 4.44 .+-. 3.71 0.38
IPSS 8.00 .+-. 10.72 6.00 .+-. 8.00 0.64
TABLE-US-00004 TABLE (4) First month Third month Avg. Avg.
Improvement status Group C of Standard of Standard P Questionnaire
score .+-. deviation score .+-. deviation unimproved unimproved
value IIEF-5 18.33 .+-. 6.54 20 .+-. 5.69 0.33 26 QEQ 19.57 .+-.
7.53 22.53 .+-. 8.02 0.24 PEDT 5.14 .+-. 4.22 3.16 .+-. 3.76 0.12
IPSS 3.86 .+-. 6.40 2.58 .+-. 4.06 0.45
[0083] Therefore, data of clinical trials have proved that, after
wearing the underpants provided by the present invention for three
months, both the men diagnosed with sexual dysfunction and the men
not sure to suffer from sexual dysfunction have an apparent
progress on improvements of their erectile ability, erectile
quality, ejaculation control ability, and lower urinary tract
symptoms (LUTS).
[0084] It is worth explaining that, the far-infrared fibers 11
contained by the underpants 1 (as FIG. 5 shows) would emit
electromagnetic radiation in the far infrared region (wavelength
4-14 microns). Such far-infrared rays have been examined for
effects on human leukocyte activity and on lipid peroxidation of
unsaturated fatty acids. Moreover, related research also report
that far-infrared rays significantly increase intracellular calcium
ion concentration, phagocytosis, and generation of reactive oxygen
species in neutrophils, and the blastogenetic response of
lymphocytes to mitogens. Despite the increase in reactive oxygen
species generated by neutrophils, lipid peroxidation from
unsaturated fatty acid may be markedly inhibited by far-infrared
rays, related research suggest that the far-infrared rays can be
widely used for cosmetic, therapeutic, and preservative purposes,
appear capable of potentiating leukocyte functions without
promoting oxidative injury. On the other hand, far-infrared ray
(FIR) radiation has been proved to be beneficial to human health.
Particularly, related research have investigated the effect carried
out by FIR on the expression of calmodulin (Cam) protein and nitric
oxide (NO) production in human body. Experimental data indicated a
significant increase in Cam protein in FIR-treated RAW 264.7
macrophages with or without the addition of lipopolysaccharide
(LPS). In addition, the amount of NO was slightly higher but
increased significantly in FIR plus LPS-treated RAW 264.7
macrophages.
[0085] It is worth explaining that, the physiologic mechanism of
erection of the penis involves release of nitric oxide (NO) in the
corpus cavernosum during sexual stimulation. Related research
indicates that NO would activate the enzyme guanylate cyclase,
which results in increased levels of cyclic guanosine monophosphate
(cGMP), so as to produce smooth muscle relaxation in the corpus
cavernosum and allowing inflow of blood. NO in vascular regulation
couples endothelial and smooth muscle cells. In blood vessels,
vascular dilation is initiated by acetylcholine acting at
muscarinic receptors on endothelial cells. This initiates IP3
production, Ca.sup.2+ release from endoplasmic reticulum and
activation of NO synthase by Ca.sup.2+/calmodulin. Nitric oxide
diffuses to smooth muscle cells and activates guanylyl cyclase.
cGMP activates a cGMP-dependent protein kinase which phosphorylates
myosin light chain and causes vascular relaxation.
[0086] It is repeated that, when an adult man wear this underpants
1 (as shown in FIG. 5), the far-infrared rays emitted from the
front rise portion 13 and the crotch portion 14 of the underpants 1
would make the dilation of penile arteries of the adult man, and
simultaneously urge blood to flow into the penile arteries so as to
make the erection of the adult man's penis. Accordingly,
physiological data of the test subjects measured by nursing
personnel are integrated in following Table (5), Table (6) and
Table (7). Therefore, the recorded physiological data have proved
that, despite the fact that the adult men wear the underpants
provided by the present invention for three months, there is no any
adverse effect induced by the underpants so as to cause the
physiological condition of the men be abnormal.
TABLE-US-00005 TABLE 5 First month Standard physiological data
Average .+-. deviation Maximum Minimum SBP (mmHg) 126.64 .+-. 9.92
147.00 108.00 DBP (mmHg) 80.86 .+-. 9.13 98.00 64.00 Body Temp.
(.degree. C.) 36.37 .+-. 0.56 37.2 35.00 Pulse (bit/min) 73.29 .+-.
7.25 93.00 64.00
TABLE-US-00006 TABLE 6 Second month Standard physiological data
Average .+-. deviation Maximum Minimum SBP (mmHg) 123.33 .+-. 8.50
140.00 110.00 DBP (mmHg) 83.44 .+-. 6.64 92.00 71.00 Body Temp.
(.degree. C.) 36.64 .+-. 0.29 37.00 36.20 Pulse (bit/min) 74.44
.+-. 8.23 96.00 64.00
TABLE-US-00007 TABLE 7 Third month Standard physiological data
Average .+-. deviation Maximum Minimum SBP (mmHg) 126.00 .+-. 8.29
135.00 115.00 DBP (mmHg) 84.00 .+-. 7.79 93.00 74.00 Body Temp.
(.degree. C.) 36.20 .+-. 0.28 36.60 36.00 Pulse (bit/min) 73.67
.+-. 12.12 90.00 61.00
[0087] Therefore, through above descriptions, the method for
treating male sexual dysfunction by using underpants comprising
far-infrared fibers proposed by the present invention have been
introduced completely and clearly; in summary, the present
invention includes the advantages of:
[0088] (1) Differing from conventional approaches for improving
sexual dysfunction of an adult man being commonly carried out by
letting the adult man administer a dosage of synthetic drug or a
composition of Chinese herbal medicines, the present invention
particularly discloses a method for treating male sexual
dysfunction by using underpants comprising far-infrared fibers. A
variety of clinical data have proved that, after wearing this
underpants for three months, both the men diagnosed with sexual
dysfunction and the men not sure to suffer from sexual dysfunction
have an apparent progress on improvements of their erectile
ability, erectile quality, ejaculation control ability, and lower
urinary tract symptoms (LUTS).
[0089] (2) Moreover, clinical data have also proved that, despite
the fact that a male person wears the underpants provided by the
present invention for three months, there is no adverse effect
induced by the underpants for causing the physiological condition
of the men be abnormal.
[0090] The above description is made on embodiments of the present
invention. However, the embodiments are not intended to limit scope
of the present invention, and all equivalent implementations or
alterations within the spirit of the present invention still fall
within the scope of the present invention.
* * * * *